Eli Lilly and Company Share Price and Fundamentals (LLY)

Overview

Eli Lilly and Company has become one of the market’s standout healthcare names, with the share price at $1,255.40 after a gain of $11.00, or 0.88%, in the latest session. The stock sits close to its 52-week high of $1,292.65 and well above its 52-week low of $689.88, reflecting the scale of investor confidence in its diabetes, obesity and broader pharmaceutical portfolio. For Australian investors scanning US healthcare exposure, Lilly stands out not for yield, but for growth, profitability and its dominant place in a fast-expanding therapeutic market.

Lilly is a global drug manufacturer focused on human pharmaceuticals across cardiometabolic health, oncology, immunology and neuroscience. Its most visible growth engines include Mounjaro and Zepbound, while established products such as Humalog, Jardiance and Trulicity continue to support the business. The company also has a broad oncology and immunology franchise, giving it a mix of mature cash generators and newer growth assets. That breadth matters because Lilly is not simply a single-product story, even if the market’s attention has been heavily centred on its weight-loss and diabetes pipeline and portfolio. Financially, the company is operating at a very large scale, with revenue of $79.7B and a market value of 1.1T. Profitability is also strong, with a profit margin of 33.53%, while revenue growth of 47.70% points to a business still expanding at a rapid pace for its size. The dividend profile is modest, with a yield of 0.50% and dividend share of $6.46, so the investment case is primarily built around earnings growth rather than income.

Key facts

Price and trend

Valuation

At $1,255.40, Lilly trades on a price-to-earnings ratio of 42.93 and a PEG ratio of 1.61, which signals a premium valuation even by large-cap healthcare standards. That premium is not unusual for a company delivering both scale and exceptional growth, but it does mean expectations remain elevated. The analyst target price of $1,310.90 sits 4.42% above the last price, which suggests the market is already discounting much of the near-term optimism. In other words, Lilly’s valuation reflects a high-quality growth franchise, but investors are paying up for that quality.

Profitability and growth

Analyst view

Sentiment from analysts is constructive. Lilly carries a rating of 4.258 across 31 analysts, with 18 strong buy ratings, 6 buy ratings, 5 hold ratings, 1 sell rating and 1 strong sell rating. That spread shows a meaningful leaning toward optimism, even if not every broker shares the same enthusiasm. The secondary message is that the investment case is still heavily tied to execution: the company needs to keep translating commercial momentum into durable earnings growth if the market is going to justify the current multiple. From a technical perspective, the share price is trading 6.64% above the 50-day moving average of $1,177.20 and 19.43% above the 200-day moving average of $1,051.19, which indicates strong medium- and longer-term momentum. The current price also remains close to the 52-week high, reinforcing the view that the market continues to price in substantial confidence.

ETFs Featuring LLY

Risks

The main risk is valuation. With the shares already near their 52-week high and trading on a premium earnings multiple, any disappointment in product momentum, pricing, regulation or pipeline execution could weigh on sentiment quickly. Lilly’s heavy exposure to high-profile cardiometabolic drugs also means investor expectations are tied closely to the durability of demand in obesity and diabetes. Competition in pharmaceuticals is another ongoing issue, particularly across large therapeutic categories where rivals are also investing aggressively. From a market perspective, the stock’s beta of 0.51 suggests lower day-to-day volatility than the broader market, but that does not remove the possibility of sharp re-rating risk if growth slows or margins come under pressure. The small dividend also means shareholders are relying much more on growth than on income.

FAQ